Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?
作者信息
O'Reilly Eileen M, Ferrone Cristina
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY.
Weill Cornell Medical College, New York, NY.
出版信息
J Clin Oncol. 2020 Jun 1;38(16):1757-1759. doi: 10.1200/JCO.19.03318. Epub 2020 Mar 2.
Abstract
摘要
相似文献
1
Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred?
J Clin Oncol. 2020 Jun 1;38(16):1757-1759. doi: 10.1200/JCO.19.03318. Epub 2020 Mar 2.
2
Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer.
J Clin Oncol. 2022 Oct 1;40(28):3346. doi: 10.1200/JCO.22.00432. Epub 2022 Jun 23.
3
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
4
Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
Semin Radiat Oncol. 2014 Apr;24(2):113-25. doi: 10.1016/j.semradonc.2013.11.002.
5
Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
Updates Surg. 2016 Sep;68(3):235-239. doi: 10.1007/s13304-016-0392-x. Epub 2016 Sep 15.
6
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
Int J Mol Sci. 2017 Jul 26;18(8):1622. doi: 10.3390/ijms18081622.
7
[Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
Chirurg. 2020 May;91(5):391-395. doi: 10.1007/s00104-019-01093-7.
8
New developments in the management of borderline resectable pancreatic cancers.
JOP. 2013 Jul 10;14(4):334-6. doi: 10.6092/1590-8577/1681.
9
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
BMC Cancer. 2019 Jul 9;19(1):675. doi: 10.1186/s12885-019-5889-5.
10
[Borderline resectable pancreatic cancer - a definition and effective treatment strategy].
Gan To Kagaku Ryoho. 2012 Mar;39(3):337-41.
引用本文的文献
1
The immune-related prognostic gene AIM2 promotes pancreatic cancer progression via inflammasome.
Sci Rep. 2025 Aug 13;15(1):29733. doi: 10.1038/s41598-025-12651-x.
2
Phospholipid-Rich DC-Vesicles with Preserved Immune Fingerprints: A Stable and Scalable Platform for Precision Immunotherapy.
Biomedicines. 2025 May 26;13(6):1299. doi: 10.3390/biomedicines13061299.
3
Interview with Prof. Dr. Jeffrey Drebin, President of the 2024 President Elect of the American Surgical Association.
Ann Gastroenterol Surg. 2024 Nov 22;9(1):24-31. doi: 10.1002/ags3.12882. eCollection 2025 Jan.
4
Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis.
Cancers (Basel). 2024 Sep 20;16(18):3203. doi: 10.3390/cancers16183203.
5
Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery.
Curr Oncol. 2024 Apr 15;31(4):2260-2273. doi: 10.3390/curroncol31040167.
6
Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.
PLoS One. 2024 Mar 7;19(3):e0295983. doi: 10.1371/journal.pone.0295983. eCollection 2024.
7
Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Cancer Med. 2023 Jun;12(12):12986-12995. doi: 10.1002/cam4.5971. Epub 2023 May 3.
8
Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma.
JAMA Netw Open. 2022 Dec 1;5(12):e2248147. doi: 10.1001/jamanetworkopen.2022.48147.
9
Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer.
Front Oncol. 2022 Feb 21;12:841819. doi: 10.3389/fonc.2022.841819. eCollection 2022.
10
Roles and Clinical Significances of ATF6, EMC6, and APAF1 in Prognosis of Pancreatic Cancer.
Front Genet. 2022 Feb 11;12:730847. doi: 10.3389/fgene.2021.730847. eCollection 2021.
本文引用的文献
1
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.
2
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
J Natl Cancer Inst. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073.
3
Pancreatic Adenocarcinoma, Version 1.2019.
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.
4
Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis.
Pancreas. 2019 Feb;48(2):216-222. doi: 10.1097/MPA.0000000000001231.
5
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
6
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
7
A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
Ann Surg. 2018 Oct;268(4):610-619. doi: 10.1097/SLA.0000000000002957.
8
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
9
Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.
World J Surg Oncol. 2017 Oct 10;15(1):183. doi: 10.1186/s12957-017-1240-2.
10
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.
Zotero 插件